AXON presenteert op CTAD aanvullende onderzoeksresultaten van achttien maanden vervolgonderzoek na Fase 1
SAN DIEGO–(BUSINESS WIRE)– AXON Neuroscience heeft de resultaten na achttien maanden van het vervolgonderzoek naar een actief tau-vaccin gepresenteerd op de negende International Conference on Clinical Trials in Alzheimer’s Disease (CTAD) in San Diego. Deze resultaten bevestigen ook na langere observatie de onderzoeksresultaten van het fase 1-onderzoek naar dit middel.
Het primaire doel van het vervolgonderzoek was de veiligheid, verdraagbaarheid en immunogeniciteit van AADvac1 te beoordelen na een extra periode van achttien maanden. De patiënten kregen twee extra boostervaccins van AADvac1, om er zeker van te zijn dat de therapeutische antistoffen zouden aanblijven.
Matej Ondrus, medisch topman van AXON, zei op CTAD dat het onderzoek aantoont dat AADvac1 over het algemeen voor uitmuntende resultaten zorgt na een behandeling van Alzheimer patiënten gedurende 24 maanden in totaal.
AXON Presented at CTAD the Additional Results from the 18 Months Follow up of the Phase I Study |
|||||
|
SAN DIEGO–(BUSINESS WIRE)– AXON Neuroscience presented the results of the 18 month follow-up study with an active tau vaccine at the 9th International Conference on Clinical Trials in Alzheimer’s Disease (CTAD) in San Diego (US). These results have confirmed in longer observation the encouraging phase I study results. The detailed phase I study results were published in The Lancet Neurology on December 9 th 2016.
FOLLOW UP STUDY WITH THE AADVAC 1 VACCINE The primary objective of the follow-up study was to assess the long-term safety and tolerability of AADvac1 and immunogenicity over a period of an additional 18 months. The patients received two additional AADvac1 booster vaccinations aiming to ensure persistence of induced therapeutic antibodies. At CTAD, AXON’s Medical Director, Matej Ondrus, announced that the study confirmed overall excellent results of AADvac1 in a total treatment period of 24 months in patients with Alzheimer’s disease. Additionally, the study confirmed the ability of the booster vaccines to sustain the desired immune response. “While already in the Phase II study, AADvac1 is currently the most advanced tau disease modifying therapy in the field with the potential to be used also as a preventive treatment for AD”, said Matej Ondrus. AADVAC1 TAU VACCINE AADvac1 is an active tau vaccine against Alzheimer’s disease and related tauopathies. AADvac1 is designed to elicit antibodies against the pathological tau protein, which is the primary cause of neurofibrillary pathology in Alzheimer’s disease. These antibodies are expected to prevent the tau protein from pathological interactions, and thus to stop the progress of Alzheimer’s disease and neurodegeneration. AXON NEUROSCIENCE AXON Neuroscience is a clinical-stage biotech company developing disease-modifying therapeutics for Alzheimer’s disease and other tauopathies. AXON is the first company which has successfully launched a Phase 2 study with a disease-modifying active immunotherapy against pathologically modified tau protein. The Phase 2 study is conducted in 8 European countries and has already recruited 44 out of 185 participating patients with mild AD. View source version on businesswire.com: http://www.businesswire.com/news/home/20161213005948/en/ Contacts AXON Neuroscience |
|||||